August 13, 2025

Temporal optimization of CD25-biased IL-2 agonists and immune checkpoint blockade leads to synergistic anticancer activity despite robust regulatory T cell expansion.

View Full Paper

Ask AI

Bookmark

Administration of CD25-biased IL-2cx after immune checkpoint inhibitors led to significant tumor growth reduction.
Combination treatment completely eradicated established tumors despite increased regulatory T cell expansion.
Mechanistic insights reveal that CD25-biased IL-2cx boosts CD8+ T cell functions while reducing toxicity compared to CD25-blocking variants.
Study findings emphasize the importance of timing for IL-2cx use in enhancing efficacy of cancer immunotherapy.

Discussion

No takes yet. Share an insight, caveat, or question.

Combination of CD25-biased IL-2cx and immune checkpoint inhibitors demonstrates improved tumor eradication in mice, highlighting timing in therapy.

Kılıç et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Combination of CD25-biased IL-2cx and immune checkpoint inhibitors demonstrates improved tumor eradication in mice, highlighting timing in therapy.